{
  "docId": "019de074-05b7-71fd-bc3c-27f1b7be8924",
  "docSlug": "c3cb552ef3a6b077a714c97117e1fe86",
  "documentTitle": "Mink Therapeutics | Investor Day Presentation Deck | 92 slides",
  "authorId": "mink-therapeutics",
  "authorName": "MiNK Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 92,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 36,
  "notes": "The table displays patient characteristics (age, sex) and disposition (early discontinuation, death, progression) for three distinct dosing groups and the total population.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-05b7-71fd-bc3c-27f1b7be8924/30",
  "deckHref": "/decks/019de074-05b7-71fd-bc3c-27f1b7be8924",
  "deckJsonHref": "/decks/019de074-05b7-71fd-bc3c-27f1b7be8924.json",
  "deckAnchorHref": "/decks/019de074-05b7-71fd-bc3c-27f1b7be8924#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.65,
        "y": 0.35
      },
      "kind": "list",
      "text": "Trial Launch May 2022; Efficacy Evaluable/Enrolled: 14/25; Heavily pretreated with median ~4 prior lines of therapy; Median follow-up ~18 weeks; Favorable safety; no CRS or neurotoxicity",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dec2a446-697a-4d6c-8af4-9fc9a6f3a69b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.6,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "table",
      "text": "Patient demographics and disposition table",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76e893a5-ad4e-4b3d-a7ec-45e366233533",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "Phase 1 Trial of agent-797 (allo-iNKTs) Monotherapy or in Combination with Pembrolizumab or Nivolumab in Solid Tumors",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05bbaace-2729-4413-b785-0a0369c2f6c7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "cbaf0062-6bef-404c-824d-a7cb6d683aa3",
      "evidence": "table/data: Patient demographics and disposition table",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 35,
      "from": 23,
      "beatId": "3ca2588f-ae86-4809-9434-ea06292b2cdd",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence",
      "beatSlug": "evidence",
      "evidence": "The presentation provides preclinical and clinical data supporting iNKT cells' potential",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 35,
      "from": 23,
      "name": "Before After",
      "slug": "21-before-after",
      "bestFor": "Product demos, process improvements, ROI justification",
      "matchId": "d3a14978-bf9f-4a75-b0e8-87c8ef56ddbf",
      "evidence": "The presentation uses before-after comparisons to show iNKT cells' potential",
      "position": 1,
      "objective": "Illustrating the benefits of iNKT cells",
      "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
      "confidence": 0.7,
      "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}